ID   FAK1_HUMAN              Reviewed;        1052 AA.
AC   Q05397; B4E2N6; F5H4S4; J3QT16; Q14291; Q8IYN9; Q9UD85;
DT   01-FEB-1994, integrated into UniProtKB/Swiss-Prot.
DT   15-JUL-1998, sequence version 2.
DT   10-MAY-2017, entry version 210.
DE   RecName: Full=Focal adhesion kinase 1;
DE            Short=FADK 1;
DE            EC=2.7.10.2;
DE   AltName: Full=Focal adhesion kinase-related nonkinase;
DE            Short=FRNK;
DE   AltName: Full=Protein phosphatase 1 regulatory subunit 71;
DE            Short=PPP1R71;
DE   AltName: Full=Protein-tyrosine kinase 2;
DE   AltName: Full=p125FAK;
DE   AltName: Full=pp125FAK;
GN   Name=PTK2; Synonyms=FAK, FAK1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY.
RC   TISSUE=T-cell;
RX   PubMed=7692878; DOI=10.1089/dna.1993.12.823;
RA   Whitney G.S., Chan P.Y., Blake J., Cosand W.L., Neubauer M.G.,
RA   Aruffo A., Kanner S.B.;
RT   "Human T and B lymphocytes express a structurally conserved focal
RT   adhesion kinase, pp125FAK.";
RL   DNA Cell Biol. 12:823-830(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2; 3 AND 4), AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Brain;
RX   PubMed=8422239; DOI=10.1006/bbrc.1993.1022;
RA   Andre E., Becker-Andre M.;
RT   "Expression of an N-terminally truncated form of human focal adhesion
RT   kinase in brain.";
RL   Biochem. Biophys. Res. Commun. 190:140-147(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 5).
RC   TISSUE=Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16421571; DOI=10.1038/nature04406;
RA   Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S.,
RA   Garber M., Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A.,
RA   Chang J.L., Cuomo C.A., Dewar K., FitzGerald M.G., Yang X.,
RA   Allen N.R., Anderson S., Asakawa T., Blechschmidt K., Bloom T.,
RA   Borowsky M.L., Butler J., Cook A., Corum B., DeArellano K.,
RA   DeCaprio D., Dooley K.T., Dorris L. III, Engels R., Gloeckner G.,
RA   Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K., Jaffe D.B.,
RA   Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P.,
RA   Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H.,
RA   Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C.,
RA   O'Leary S.B., O'Neill K., Parker S.C.J., Polley A., Raymond C.K.,
RA   Reichwald K., Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R.,
RA   Smith C.L., Sneddon T.P., Talamas J.A., Tenzin P., Topham K.,
RA   Venkataraman V., Wen G., Yamazaki S., Young S.K., Zeng Q.,
RA   Zimmer A.R., Rosenthal A., Birren B.W., Platzer M., Shimizu N.,
RA   Lander E.S.;
RT   "DNA sequence and analysis of human chromosome 8.";
RL   Nature 439:331-335(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 7).
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PROTEIN SEQUENCE OF 2-19; 192-199; 222-236; 243-252; 350-364; 414-419;
RP   468-476; 562-569; 674-690; 798-811; 832-838; 904-933; 963-981;
RP   989-1000 AND 1003-1042, CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION
RP   AT ALA-2, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Osteosarcoma;
RA   Bienvenut W.V., Glen H., Brunton V.G., Frame M.C.;
RL   Submitted (JUL-2007) to UniProtKB.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 552-602, AND TISSUE SPECIFICITY.
RC   TISSUE=Melanocyte;
RX   PubMed=8247543;
RA   Lee S.-T., Strunk K.M., Spritz R.A.;
RT   "A survey of protein tyrosine kinase mRNAs expressed in normal human
RT   melanocytes.";
RL   Oncogene 8:3403-3410(1993).
RN   [8]
RP   INTERACTION WITH TGFB1I1.
RX   PubMed=9422762; DOI=10.1074/jbc.273.2.1003;
RA   Matsuya M., Sasaki H., Aoto H., Mitaka T., Nagura K., Ohba T.,
RA   Ishino M., Takahashi S., Suzuki R., Sasaki T.;
RT   "Cell adhesion kinase beta forms a complex with a new member, Hic-5,
RT   of proteins localized at focal adhesions.";
RL   J. Biol. Chem. 273:1003-1014(1998).
RN   [9]
RP   INTERACTION WITH TGFB1I1, AND MUTAGENESIS OF VAL-928 AND LEU-1034.
RX   PubMed=9756887; DOI=10.1074/jbc.273.41.26516;
RA   Fujita H., Kamiguchi K., Cho D., Shibanuma M., Morimoto C.,
RA   Tachibana K.;
RT   "Interaction of Hic-5, A senescence-related protein, with focal
RT   adhesion kinase.";
RL   J. Biol. Chem. 273:26516-26521(1998).
RN   [10]
RP   FUNCTION IN PXN PHOSPHORYLATION; REGULATION OF CELL SHAPE AND
RP   MIGRATION, INTERACTION WITH EPHA2, AUTOPHOSPHORYLATION, CATALYTIC
RP   ACTIVITY, ENZYME REGULATION, DEPHOSPHORYLATION BY PTPN11, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=10655584; DOI=10.1038/35000008;
RA   Miao H., Burnett E., Kinch M., Simon E., Wang B.;
RT   "Activation of EphA2 kinase suppresses integrin function and causes
RT   focal-adhesion-kinase dephosphorylation.";
RL   Nat. Cell Biol. 2:62-69(2000).
RN   [11]
RP   FUNCTION IN CELL MIGRATION AND ACTIVATION OF BMX, CATALYTIC ACTIVITY,
RP   AUTOPHOSPHORYLATION, MUTAGENESIS OF TYR-397, AND INTERACTION WITH BMX.
RX   PubMed=11331870; DOI=10.1038/35074500;
RA   Chen R., Kim O., Li M., Xiong X., Guan J.L., Kung H.J., Chen H.,
RA   Shimizu Y., Qiu Y.;
RT   "Regulation of the PH-domain-containing tyrosine kinase Etk by focal
RT   adhesion kinase through the FERM domain.";
RL   Nat. Cell Biol. 3:439-444(2001).
RN   [12]
RP   FUNCTION IN PHOSPHORYLATION OF SHC1, AUTOPHOSPHORYLATION, INTERACTION
RP   WITH SHC1 AND SRC, AND ROLE IN DISEASE.
RX   PubMed=11980671;
RA   Hecker T.P., Grammer J.R., Gillespie G.Y., Stewart J. Jr.,
RA   Gladson C.L.;
RT   "Focal adhesion kinase enhances signaling through the
RT   Shc/extracellular signal-regulated kinase pathway in anaplastic
RT   astrocytoma tumor biopsy samples.";
RL   Cancer Res. 62:2699-2707(2002).
RN   [13]
RP   INTERACTION WITH RB1CC1.
RX   PubMed=12221124; DOI=10.1091/mbc.E02-05-0295;
RA   Abbi S., Ueda H., Zheng C., Cooper L.A., Zhao J., Christopher R.,
RA   Guan J.L.;
RT   "Regulation of focal adhesion kinase by a novel protein inhibitor
RT   FIP200.";
RL   Mol. Biol. Cell 13:3178-3191(2002).
RN   [14]
RP   PHOSPHORYLATION AT TYR-397; TYR-407; TYR-577; TYR-861 AND TYR-925, AND
RP   INTERACTION WITH FGR.
RX   PubMed=12387730; DOI=10.1042/BJ20020410;
RA   Relou I.A.M., Bax L.A.B., Van Rijn H.J.M., Akkerman J.-W.N.;
RT   "Site-specific phosphorylation of platelet focal adhesion kinase by
RT   low-density lipoprotein.";
RL   Biochem. J. 369:407-416(2003).
RN   [15]
RP   FUNCTION IN INTEGRIN SIGNALING; REGULATION OF APOPTOSIS; REGULATION OF
RP   CELL SHAPE AND ACTIVATION OF PHOSPHATIDYLINOSITOL KINASE AND AKT1
RP   SIGNALING PATHWAY.
RX   PubMed=15166238; DOI=10.1074/jbc.M313265200;
RA   Xia H., Nho R.S., Kahm J., Kleidon J., Henke C.A.;
RT   "Focal adhesion kinase is upstream of phosphatidylinositol 3-
RT   kinase/Akt in regulating fibroblast survival in response to
RT   contraction of type I collagen matrices via a beta 1 integrin
RT   viability signaling pathway.";
RL   J. Biol. Chem. 279:33024-33034(2004).
RN   [16]
RP   FUNCTION IN REGULATION OF CELL MIGRATION, AND PHOSPHORYLATION AT
RP   TYR-407; TYR-397 AND TYR-576.
RX   PubMed=15561106; DOI=10.1016/j.yexcr.2004.09.005;
RA   Continolo S., Baruzzi A., Majeed M., Caveggion E., Fumagalli L.,
RA   Lowell C.A., Berton G.;
RT   "The proto-oncogene Fgr regulates cell migration and this requires its
RT   plasma membrane localization.";
RL   Exp. Cell Res. 302:253-269(2005).
RN   [17]
RP   INTERACTION WITH P53/TP53, AND SUBCELLULAR LOCATION.
RX   PubMed=15855171; DOI=10.1074/jbc.M414172200;
RA   Golubovskaya V.M., Finch R., Cance W.G.;
RT   "Direct interaction of the N-terminal domain of focal adhesion kinase
RT   with the N-terminal transactivation domain of p53.";
RL   J. Biol. Chem. 280:25008-25021(2005).
RN   [18]
RP   FUNCTION IN FOCAL ADHESION DISASSEMBLY.
RX   PubMed=15895076; DOI=10.1038/ncb1262;
RA   Ezratty E.J., Partridge M.A., Gundersen G.G.;
RT   "Microtubule-induced focal adhesion disassembly is mediated by dynamin
RT   and focal adhesion kinase.";
RL   Nat. Cell Biol. 7:581-590(2005).
RN   [19]
RP   INTERACTION WITH FLT4.
RX   PubMed=16452200; DOI=10.1158/0008-5472.CAN-05-1661;
RA   Garces C.A., Kurenova E.V., Golubovskaya V.M., Cance W.G.;
RT   "Vascular endothelial growth factor receptor-3 and focal adhesion
RT   kinase bind and suppress apoptosis in breast cancer cells.";
RL   Cancer Res. 66:1446-1454(2006).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [21]
RP   ALTERNATIVE PROMOTER USAGE, IDENTIFICATION OF ISOFORM 6, AND
RP   DEVELOPMENTAL STAGE (ISOFORM 6).
RX   PubMed=16998626; DOI=10.1007/s00795-006-0325-8;
RA   Nagoshi Y., Yamamoto G., Irie T., Tachikawa T.;
RT   "Expression of FAK-related non-kinase (FRNK) coincides with
RT   morphological change in the early stage of cell adhesion.";
RL   Med. Mol. Morphol. 39:154-160(2006).
RN   [22]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [23]
RP   ENZYME REGULATION, ROLE IN DISEASE, AND PHOSPHORYLATION AT TYR-397 AND
RP   TYR-861.
RX   PubMed=18006843; DOI=10.1158/0008-5472.CAN-07-2667;
RA   Halder J., Lin Y.G., Merritt W.M., Spannuth W.A., Nick A.M., Honda T.,
RA   Kamat A.A., Han L.Y., Kim T.J., Lu C., Tari A.M., Bornmann W.,
RA   Fernandez A., Lopez-Berestein G., Sood A.K.;
RT   "Therapeutic efficacy of a novel focal adhesion kinase inhibitor
RT   TAE226 in ovarian carcinoma.";
RL   Cancer Res. 67:10976-10983(2007).
RN   [24]
RP   FUNCTION, ENZYME REGULATION, ROLE IN DISEASE, AND PHOSPHORYLATION AT
RP   TYR-397.
RX   PubMed=17395594; DOI=10.1074/jbc.M606695200;
RA   Slack-Davis J.K., Martin K.H., Tilghman R.W., Iwanicki M., Ung E.J.,
RA   Autry C., Luzzio M.J., Cooper B., Kath J.C., Roberts W.G.,
RA   Parsons J.T.;
RT   "Cellular characterization of a novel focal adhesion kinase
RT   inhibitor.";
RL   J. Biol. Chem. 282:14845-14852(2007).
RN   [25]
RP   FUNCTION IN OSTEOBLAST DIFFERENTIATION.
RX   PubMed=16927379; DOI=10.1002/jcb.21074;
RA   Salasznyk R.M., Klees R.F., Boskey A., Plopper G.E.;
RT   "Activation of FAK is necessary for the osteogenic differentiation of
RT   human mesenchymal stem cells on laminin-5.";
RL   J. Cell. Biochem. 100:499-514(2007).
RN   [26]
RP   FUNCTION, ENZYME REGULATION, ROLE IN DISEASE, AND PHOSPHORYLATION AT
RP   TYR-397.
RX   PubMed=17431114; DOI=10.1158/1535-7163.MCT-06-0476;
RA   Liu T.J., LaFortune T., Honda T., Ohmori O., Hatakeyama S., Meyer T.,
RA   Jackson D., de Groot J., Yung W.K.;
RT   "Inhibition of both focal adhesion kinase and insulin-like growth
RT   factor-I receptor kinase suppresses glioma proliferation in vitro and
RT   in vivo.";
RL   Mol. Cancer Ther. 6:1357-1367(2007).
RN   [27]
RP   FUNCTION, AND INTERACTION WITH LPXN.
RX   PubMed=18497331; DOI=10.1161/CIRCRESAHA.107.170357;
RA   Sundberg-Smith L.J., DiMichele L.A., Sayers R.L., Mack C.P.,
RA   Taylor J.M.;
RT   "The LIM protein leupaxin is enriched in smooth muscle and functions
RT   as an serum response factor cofactor to induce smooth muscle cell gene
RT   transcription.";
RL   Circ. Res. 102:1502-1511(2008).
RN   [28]
RP   FUNCTION, AND INTERACTION WITH BMX.
RX   PubMed=18292575; DOI=10.4049/jimmunol.180.5.3485;
RA   Semaan N., Alsaleh G., Gottenberg J.E., Wachsmann D., Sibilia J.;
RT   "Etk/BMX, a Btk family tyrosine kinase, and Mal contribute to the
RT   cross-talk between MyD88 and FAK pathways.";
RL   J. Immunol. 180:3485-3491(2008).
RN   [29]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH CASS4.
RX   PubMed=18256281; DOI=10.1091/mbc.E07-09-0953;
RA   Singh M.K., Dadke D., Nicolas E., Serebriiskii I.G., Apostolou S.,
RA   Canutescu A., Egleston B.L., Golemis E.A.;
RT   "A novel Cas family member, HEPL, regulates FAK and cell spreading.";
RL   Mol. Biol. Cell 19:1627-1636(2008).
RN   [30]
RP   FUNCTION IN REGULATION OF P53/TP53 LEVELS; CELL PROLIFERATION AND CELL
RP   SURVIVAL, AND SUBCELLULAR LOCATION.
RX   PubMed=18206965; DOI=10.1016/j.molcel.2007.11.031;
RA   Lim S.T., Chen X.L., Lim Y., Hanson D.A., Vo T.T., Howerton K.,
RA   Larocque N., Fisher S.J., Schlaepfer D.D., Ilic D.;
RT   "Nuclear FAK promotes cell proliferation and survival through FERM-
RT   enhanced p53 degradation.";
RL   Mol. Cell 29:9-22(2008).
RN   [31]
RP   INTERACTION WITH ESR1; PIK3R1 AND/OR PIK3R2 AND SRC.
RX   PubMed=18657504; DOI=10.1016/j.molcel.2008.05.025;
RA   Le Romancer M., Treilleux I., Leconte N., Robin-Lespinasse Y.,
RA   Sentis S., Bouchekioua-Bouzaghou K., Goddard S., Gobert-Gosse S.,
RA   Corbo L.;
RT   "Regulation of estrogen rapid signaling through arginine methylation
RT   by PRMT1.";
RL   Mol. Cell 31:212-221(2008).
RN   [32]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-13; SER-29; SER-887 AND
RP   SER-910, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [33]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-910, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [34]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [35]
RP   PHOSPHORYLATION AT TYR-397; TYR-576; TYR-577; SER-722; TYR-861 AND
RP   TYR-925, AND IDENTIFICATION IN A COMPLEX WITH CTTN AND FER.
RX   PubMed=19339212; DOI=10.1016/j.bbamcr.2009.01.015;
RA   Oh M.A., Choi S., Lee M.J., Choi M.C., Lee S.A., Ko W., Cance W.G.,
RA   Oh E.S., Buday L., Kim S.H., Lee J.W.;
RT   "Specific tyrosine phosphorylation of focal adhesion kinase mediated
RT   by Fer tyrosine kinase in suspended hepatocytes.";
RL   Biochim. Biophys. Acta 1793:781-791(2009).
RN   [36]
RP   FUNCTION IN SRC-MEDIATED PHOSPHORYLATION OF PXN.
RX   PubMed=19138410; DOI=10.1186/1471-2407-9-12;
RA   Sachdev S., Bu Y., Gelman I.H.;
RT   "Paxillin-Y118 phosphorylation contributes to the control of Src-
RT   induced anchorage-independent growth by FAK and adhesion.";
RL   BMC Cancer 9:12-12(2009).
RN   [37]
RP   INTERACTION WITH STEAP4.
RX   PubMed=19787193; DOI=10.3892/ijmm_00000270;
RA   Tamura T., Chiba J.;
RT   "STEAP4 regulates focal adhesion kinase activation and CpG motifs
RT   within STEAP4 promoter region are frequently methylated in DU145,
RT   human androgen-independent prostate cancer cells.";
RL   Int. J. Mol. Med. 24:599-604(2009).
RN   [38]
RP   INTERACTION WITH EMP2.
RX   PubMed=19494199; DOI=10.1167/iovs.08-3315;
RA   Morales S.A., Mareninov S., Coulam P., Wadehra M., Goodglick L.,
RA   Braun J., Gordon L.K.;
RT   "Functional consequences of interactions between FAK and epithelial
RT   membrane protein 2 (EMP2).";
RL   Invest. Ophthalmol. Vis. Sci. 50:4949-4956(2009).
RN   [39]
RP   FUNCTION IN SRC-MEDIATED PHOSPHORYLATION OF BCAR1, AND ROLE IN
RP   DISEASE.
RX   PubMed=19147981; DOI=10.1172/JCI37160;
RA   Pylayeva Y., Gillen K.M., Gerald W., Beggs H.E., Reichardt L.F.,
RA   Giancotti F.G.;
RT   "Ras- and PI3K-dependent breast tumorigenesis in mice and humans
RT   requires focal adhesion kinase signaling.";
RL   J. Clin. Invest. 119:252-266(2009).
RN   [40]
RP   INTERACTION WITH EPHA1.
RX   PubMed=19118217; DOI=10.1242/jcs.036467;
RA   Yamazaki T., Masuda J., Omori T., Usui R., Akiyama H., Maru Y.;
RT   "EphA1 interacts with integrin-linked kinase and regulates cell
RT   morphology and motility.";
RL   J. Cell Sci. 122:243-255(2009).
RN   [41]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, PHOSPHORYLATION [LARGE
RP   SCALE ANALYSIS] AT TYR-5; THR-13; SER-29; TYR-397; TYR-570; SER-580
RP   AND SER-910, CLEAVAGE OF INITIATOR METHIONINE [LARGE SCALE ANALYSIS],
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [42]
RP   ROLE IN DISEASE, AND ENZYME REGULATION.
RX   PubMed=20495381; DOI=10.4161/cbt.10.1.11993;
RA   Sun H., Pisle S., Gardner E.R., Figg W.D.;
RT   "Bioluminescent imaging study: FAK inhibitor, PF-562,271, preclinical
RT   study in PC3M-luc-C6 local implant and metastasis xenograft models.";
RL   Cancer Biol. Ther. 10:38-43(2010).
RN   [43]
RP   INTERACTION WITH LPXN.
RX   PubMed=19917054; DOI=10.1111/j.1349-7006.2009.01398.x;
RA   Tanaka T., Moriwaki K., Murata S., Miyasaka M.;
RT   "LIM domain-containing adaptor, leupaxin, localizes in focal adhesion
RT   and suppresses the integrin-induced tyrosine phosphorylation of
RT   paxillin.";
RL   Cancer Sci. 101:363-368(2010).
RN   [44]
RP   FUNCTION (ISOFORM 6), AND TISSUE SPECIFICITY.
RX   PubMed=20109444; DOI=10.1016/j.yexcr.2010.01.021;
RA   Cai G.Q., Zheng A., Tang Q., White E.S., Chou C.F., Gladson C.L.,
RA   Olman M.A., Ding Q.;
RT   "Downregulation of FAK-related non-kinase mediates the migratory
RT   phenotype of human fibrotic lung fibroblasts.";
RL   Exp. Cell Res. 316:1600-1609(2010).
RN   [45]
RP   INTERACTION WITH ZFYVE21, AND DEPHOSPHORYLATION AT TYR-397.
RX   PubMed=20439989; DOI=10.1074/jbc.M110.106443;
RA   Nagano M., Hoshino D., Sakamoto T., Kawasaki N., Koshikawa N.,
RA   Seiki M.;
RT   "ZF21 protein regulates cell adhesion and motility.";
RL   J. Biol. Chem. 285:21013-21022(2010).
RN   [46]
RP   INTERACTION WITH CD36.
RX   PubMed=20037584; DOI=10.1038/ni.1836;
RA   Stewart C.R., Stuart L.M., Wilkinson K., van Gils J.M., Deng J.,
RA   Halle A., Rayner K.J., Boyer L., Zhong R., Frazier W.A.,
RA   Lacy-Hulbert A., El Khoury J., Golenbock D.T., Moore K.J.;
RT   "CD36 ligands promote sterile inflammation through assembly of a Toll-
RT   like receptor 4 and 6 heterodimer.";
RL   Nat. Immunol. 11:155-161(2010).
RN   [47]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-910 AND THR-914, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [48]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [49]
RP   INTERACTION WITH RET, FUNCTION IN RET PHOSPHORYLATION, AND
RP   PHOSPHORYLATION AT TYR-576 AND TYR-577.
RX   PubMed=21454698; DOI=10.1074/jbc.M110.168500;
RA   Plaza-Menacho I., Morandi A., Mologni L., Boender P.,
RA   Gambacorti-Passerini C., Magee A.I., Hofstra R.M.W., Knowles P.,
RA   McDonald N.Q., Isacke C.M.;
RT   "Focal adhesion kinase (FAK) binds RET kinase via its FERM domain,
RT   priming a direct and reciprocal RET-FAK transactivation mechanism.";
RL   J. Biol. Chem. 286:17292-17302(2011).
RN   [50]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-13; SER-29; SER-843 AND
RP   SER-910, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [51]
RP   INTERACTION WITH CIB1 ISOFORM 2.
RC   TISSUE=Brain;
RX   PubMed=23503467; DOI=10.1038/onc.2013.43;
RA   Armacki M., Joodi G., Nimmagadda S.C., de Kimpe L., Pusapati G.V.,
RA   Vandoninck S., Van Lint J., Illing A., Seufferlein T.;
RT   "A novel splice variant of calcium and integrin-binding protein 1
RT   mediates protein kinase D2-stimulated tumour growth by regulating
RT   angiogenesis.";
RL   Oncogene 33:1167-1180(2014).
RN   [52]
RP   REVIEW ON SIGNALING AND ON DIRECT PTK2/FAK1 SUBSTRATES.
RX   PubMed=10354709; DOI=10.1016/S0079-6107(98)00052-2;
RA   Schlaepfer D.D., Hauck C.R., Sieg D.J.;
RT   "Signaling through focal adhesion kinase.";
RL   Prog. Biophys. Mol. Biol. 71:435-478(1999).
RN   [53]
RP   REVIEW ON FUNCTION IN NETRIN SIGNALING.
RX   PubMed=15725728;
RA   Nikolopoulos S.N., Giancotti F.G.;
RT   "Netrin-integrin signaling in epithelial morphogenesis, axon guidance
RT   and vascular patterning.";
RL   Cell Cycle 4:E131-E135(2005).
RN   [54]
RP   REVIEW ON FUNCTION IN CELL MIGRATION; FOCAL ADHESION TURNOVER AND
RP   ACTIVATION OF SIGNALING PATHWAYS, AND ROLE IN DISEASE.
RX   PubMed=16919435; DOI=10.1016/j.ceb.2006.08.011;
RA   Mitra S.K., Schlaepfer D.D.;
RT   "Integrin-regulated FAK-Src signaling in normal and cancer cells.";
RL   Curr. Opin. Cell Biol. 18:516-523(2006).
RN   [55]
RP   FUNCTION.
RX   PubMed=17968709; DOI=10.1080/15216540701694245;
RA   Vadali K., Cai X., Schaller M.D.;
RT   "Focal adhesion kinase: an essential kinase in the regulation of
RT   cardiovascular functions.";
RL   IUBMB Life 59:709-716(2007).
RN   [56]
RP   REVIEW ON ROLE IN INTEGRIN SIGNALING AND IN REGULATION OF P53/TP53
RP   ACTIVITIES, ROLE IN DISEASE, AND ENZYME REGULATION.
RX   PubMed=18677107; DOI=10.4161/cc.6367;
RA   Lim S.T., Mikolon D., Stupack D.G., Schlaepfer D.D.;
RT   "FERM control of FAK function: implications for cancer therapy.";
RL   Cell Cycle 7:2306-2314(2008).
RN   [57]
RP   REVIEW ON FUNCTION IN REGULATION OF RHO FAMILY GTPASE ACTIVITY.
RX   PubMed=19525103; DOI=10.1016/j.ceb.2009.05.006;
RA   Tomar A., Schlaepfer D.D.;
RT   "Focal adhesion kinase: switching between GAPs and GEFs in the
RT   regulation of cell motility.";
RL   Curr. Opin. Cell Biol. 21:676-683(2009).
RN   [58]
RP   REVIEW ON EXPRESSION IN CANCER, AND ROLE IN DISEASE.
RX   PubMed=19224453; DOI=10.14670/HH-24.503;
RA   Golubovskaya V.M., Kweh F.A., Cance W.G.;
RT   "Focal adhesion kinase and cancer.";
RL   Histol. Histopathol. 24:503-510(2009).
RN   [59]
RP   REVIEW ON FUNCTION IN REGULATION OF P53/TP53.
RX   PubMed=20515733; DOI=10.2741/3653;
RA   Golubovskaya V.M., Cance W.;
RT   "Focal adhesion kinase and p53 signal transduction pathways in
RT   cancer.";
RL   Front. Biosci. 15:901-912(2010).
RN   [60]
RP   REVIEW ON ROLE IN DEVELOPMENT.
RX   PubMed=20552554; DOI=10.14670/HH-25.1039;
RA   Chatzizacharias N.A., Kouraklis G.P., Theocharis S.E.;
RT   "The role of focal adhesion kinase in early development.";
RL   Histol. Histopathol. 25:1039-1055(2010).
RN   [61]
RP   REVIEW ON FUNCTION IN INTEGRIN SIGNALING AND ACTIVATION OF DOWNSTREAM
RP   SIGNALING PATHWAYS.
RX   PubMed=20101634; DOI=10.1002/iub.303;
RA   Guan J.L.;
RT   "Integrin signaling through FAK in the regulation of mammary stem
RT   cells and breast cancer.";
RL   IUBMB Life 62:268-276(2010).
RN   [62]
RP   FUNCTION, AND SIGNALING.
RX   PubMed=20332118; DOI=10.1242/jcs.045112;
RA   Schaller M.D.;
RT   "Cellular functions of FAK kinases: insight into molecular mechanisms
RT   and novel functions.";
RL   J. Cell Sci. 123:1007-1013(2010).
RN   [63]
RP   REVIEW ON FUNCTION; SUBUNIT; PHOSPHORYLATION; ENZYME REGULATION AND
RP   ROLE IN DISEASE.
RX   PubMed=21482413; DOI=10.1016/B978-0-12-386041-5.00005-4;
RA   Hall J.E., Fu W., Schaller M.D.;
RT   "Focal adhesion kinase: exploring Fak structure to gain insight into
RT   function.";
RL   Int. Rev. Cell Mol. Biol. 288:185-225(2011).
RN   [64]
RP   INTERACTION WITH MISP.
RX   PubMed=23509069; DOI=10.1083/jcb.201207050;
RA   Zhu M., Settele F., Kotak S., Sanchez-Pulido L., Ehret L.,
RA   Ponting C.P., Goenczy P., Hoffmann I.;
RT   "MISP is a novel Plk1 substrate required for proper spindle
RT   orientation and mitotic progression.";
RL   J. Cell Biol. 200:773-787(2013).
RN   [65]
RP   X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 891-1052, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY.
RX   PubMed=12005431; DOI=10.1016/S0969-2126(02)00717-7;
RA   Arold S.T., Hoellerer M.K., Noble M.E.;
RT   "The structural basis of localization and signaling by the focal
RT   adhesion targeting domain.";
RL   Structure 10:319-327(2002).
RN   [66]
RP   X-RAY CRYSTALLOGRAPHY (1.60 ANGSTROMS) OF 411-686 IN COMPLEX WITH ATP.
RX   PubMed=12467573; DOI=10.1016/S0969-2126(02)00907-3;
RA   Nowakowski J., Cronin C.N., McRee D.E., Knuth M.W., Nelson C.G.,
RA   Pavletich N.P., Rogers J., Sang B.C., Scheibe D.N., Swanson R.V.,
RA   Thompson D.A.;
RT   "Structures of the cancer-related Aurora-A, FAK, and EphA2 protein
RT   kinases from nanovolume crystallography.";
RL   Structure 10:1659-1667(2002).
RN   [67]
RP   X-RAY CRYSTALLOGRAPHY (2.35 ANGSTROMS) OF 892-1052 IN COMPLEX WITH
RP   PXN, AND INTERACTION WITH PXN.
RX   PubMed=14527389; DOI=10.1016/j.str.2003.08.010;
RA   Hoellerer M.K., Noble M.E., Labesse G., Campbell I.D., Werner J.M.,
RA   Arold S.T.;
RT   "Molecular recognition of paxillin LD motifs by the focal adhesion
RT   targeting domain.";
RL   Structure 11:1207-1217(2003).
RN   [68]
RP   X-RAY CRYSTALLOGRAPHY (2.20 ANGSTROMS) OF 414-689 IN COMPLEX WITH
RP   INHIBITOR, CATALYTIC ACTIVITY, AND AUTOPHOSPHORYLATION.
RX   PubMed=18339875; DOI=10.1158/0008-5472.CAN-07-5155;
RA   Roberts W.G., Ung E., Whalen P., Cooper B., Hulford C., Autry C.,
RA   Richter D., Emerson E., Lin J., Kath J., Coleman K., Yao L.,
RA   Martinez-Alsina L., Lorenzen M., Berliner M., Luzzio M., Patel N.,
RA   Schmitt E., LaGreca S., Jani J., Wessel M., Marr E., Griffor M.,
RA   Vajdos F.;
RT   "Antitumor activity and pharmacology of a selective focal adhesion
RT   kinase inhibitor, PF-562,271.";
RL   Cancer Res. 68:1935-1944(2008).
RN   [69]
RP   X-RAY CRYSTALLOGRAPHY (2.82 ANGSTROMS) OF 891-1052 IN COMPLEX WITH
RP   CD4, SUBCELLULAR LOCATION, AND INTERACTION WITH CD4.
RX   PubMed=18078954; DOI=10.1016/j.jmb.2007.11.040;
RA   Garron M.L., Arthos J., Guichou J.F., McNally J., Cicala C.,
RA   Arold S.T.;
RT   "Structural basis for the interaction between focal adhesion kinase
RT   and CD4.";
RL   J. Mol. Biol. 375:1320-1328(2008).
RN   [70]
RP   VARIANTS [LARGE SCALE ANALYSIS] PRO-292; GLN-292; ALA-793; GLU-1030
RP   AND GLU-1044.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Non-receptor protein-tyrosine kinase that plays an
CC       essential role in regulating cell migration, adhesion, spreading,
CC       reorganization of the actin cytoskeleton, formation and
CC       disassembly of focal adhesions and cell protrusions, cell cycle
CC       progression, cell proliferation and apoptosis. Required for early
CC       embryonic development and placenta development. Required for
CC       embryonic angiogenesis, normal cardiomyocyte migration and
CC       proliferation, and normal heart development. Regulates axon growth
CC       and neuronal cell migration, axon branching and synapse formation;
CC       required for normal development of the nervous system. Plays a
CC       role in osteogenesis and differentiation of osteoblasts. Functions
CC       in integrin signal transduction, but also in signaling downstream
CC       of numerous growth factor receptors, G-protein coupled receptors
CC       (GPCR), EPHA2, netrin receptors and LDL receptors. Forms
CC       multisubunit signaling complexes with SRC and SRC family members
CC       upon activation; this leads to the phosphorylation of additional
CC       tyrosine residues, creating binding sites for scaffold proteins,
CC       effectors and substrates. Regulates numerous signaling pathways.
CC       Promotes activation of phosphatidylinositol 3-kinase and the AKT1
CC       signaling cascade. Promotes activation of MAPK1/ERK2, MAPK3/ERK1
CC       and the MAP kinase signaling cascade. Promotes localized and
CC       transient activation of guanine nucleotide exchange factors (GEFs)
CC       and GTPase-activating proteins (GAPs), and thereby modulates the
CC       activity of Rho family GTPases. Signaling via CAS family members
CC       mediates activation of RAC1. Recruits the ubiquitin ligase MDM2 to
CC       P53/TP53 in the nucleus, and thereby regulates P53/TP53 activity,
CC       P53/TP53 ubiquitination and proteasomal degradation.
CC       Phosphorylates SRC; this increases SRC kinase activity.
CC       Phosphorylates ACTN1, ARHGEF7, GRB7, RET and WASL. Promotes
CC       phosphorylation of PXN and STAT1; most likely PXN and STAT1 are
CC       phosphorylated by a SRC family kinase that is recruited to
CC       autophosphorylated PTK2/FAK1, rather than by PTK2/FAK1 itself.
CC       Promotes phosphorylation of BCAR1; GIT2 and SHC1; this requires
CC       both SRC and PTK2/FAK1. Promotes phosphorylation of BMX and
CC       PIK3R1. Isoform 6 (FRNK) does not contain a kinase domain and
CC       inhibits PTK2/FAK1 phosphorylation and signaling. Its enhanced
CC       expression can attenuate the nuclear accumulation of LPXN and
CC       limit its ability to enhance serum response factor (SRF)-dependent
CC       gene transcription. {ECO:0000269|PubMed:10655584,
CC       ECO:0000269|PubMed:11331870, ECO:0000269|PubMed:11980671,
CC       ECO:0000269|PubMed:15166238, ECO:0000269|PubMed:15561106,
CC       ECO:0000269|PubMed:15895076, ECO:0000269|PubMed:16919435,
CC       ECO:0000269|PubMed:16927379, ECO:0000269|PubMed:17395594,
CC       ECO:0000269|PubMed:17431114, ECO:0000269|PubMed:17968709,
CC       ECO:0000269|PubMed:18006843, ECO:0000269|PubMed:18206965,
CC       ECO:0000269|PubMed:18256281, ECO:0000269|PubMed:18292575,
CC       ECO:0000269|PubMed:18497331, ECO:0000269|PubMed:18677107,
CC       ECO:0000269|PubMed:19138410, ECO:0000269|PubMed:19147981,
CC       ECO:0000269|PubMed:19224453, ECO:0000269|PubMed:20332118,
CC       ECO:0000269|PubMed:20495381, ECO:0000269|PubMed:21454698}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028, ECO:0000269|PubMed:10655584,
CC       ECO:0000269|PubMed:11331870, ECO:0000269|PubMed:18339875}.
CC   -!- ENZYME REGULATION: Subject to autoinhibition, mediated by
CC       interactions between the FERM domain and the kinase domain.
CC       Activated by autophosphorylation at Tyr-397. This promotes
CC       interaction with SRC and phosphorylation at Tyr-576 and Tyr-577 in
CC       the kinase activation loop. Phosphorylation at Tyr-576 and Tyr-577
CC       is required for maximal kinase activity. Inhibited by TAC544,
CC       TAE226, PF-573,228 and PF-562,271. {ECO:0000269|PubMed:10655584,
CC       ECO:0000269|PubMed:17395594, ECO:0000269|PubMed:17431114,
CC       ECO:0000269|PubMed:18006843, ECO:0000269|PubMed:18677107,
CC       ECO:0000269|PubMed:20495381}.
CC   -!- SUBUNIT: Interacts (via first Pro-rich region) with CAS family
CC       members (via SH3 domain), including BCAR1, BCAR3, CASS4 and NEDD9.
CC       Interacts with GIT1. Interacts with SORBS1. Interacts with
CC       ARHGEF28. Interacts with SHB. Interacts with PXN and TLN1.
CC       Interacts with STAT1. Interacts with DCC. Interacts with WASL.
CC       Interacts with ARHGEF7. Interacts with GRB2 and GRB7 (By
CC       similarity). Component of a complex that contains at least FER,
CC       CTTN and PTK2/FAK1. Interacts with BMX. Interacts with TGFB1I1.
CC       Interacts with STEAP4. Interacts with ZFYVE21. Interacts with
CC       ESR1. Interacts with PIK3R1 or PIK3R2. Interacts with SRC, FGR,
CC       FLT4 and RET. Interacts with EPHA2 in resting cells; activation of
CC       EPHA2 recruits PTPN11, leading to dephosphorylation of PTK2/FAK1
CC       and dissociation of the complex. Interacts with EPHA1 (kinase
CC       activity-dependent). Interacts with CD4; this interaction requires
CC       the presence of HIV-1 gp120. Interacts with PIAS1. Interacts with
CC       ARHGAP26 and SHC1. Interacts with RB1CC1; this inhibits PTK2/FAK1
CC       activity and activation of downstream signaling pathways.
CC       Interacts with P53/TP53 and MDM2. Interacts with LPXN (via LD
CC       motif 3). Interacts with MISP. Interacts with CIB1 isoform 2.
CC       Interacts with CD36. Interacts with EMP2; regulates PTK2
CC       activation and localization (PubMed:19494199). {ECO:0000250,
CC       ECO:0000269|PubMed:10655584, ECO:0000269|PubMed:11331870,
CC       ECO:0000269|PubMed:11980671, ECO:0000269|PubMed:12221124,
CC       ECO:0000269|PubMed:12387730, ECO:0000269|PubMed:12467573,
CC       ECO:0000269|PubMed:14527389, ECO:0000269|PubMed:15855171,
CC       ECO:0000269|PubMed:16452200, ECO:0000269|PubMed:18078954,
CC       ECO:0000269|PubMed:18256281, ECO:0000269|PubMed:18292575,
CC       ECO:0000269|PubMed:18339875, ECO:0000269|PubMed:18497331,
CC       ECO:0000269|PubMed:18657504, ECO:0000269|PubMed:19118217,
CC       ECO:0000269|PubMed:19339212, ECO:0000269|PubMed:19494199,
CC       ECO:0000269|PubMed:19787193, ECO:0000269|PubMed:19917054,
CC       ECO:0000269|PubMed:20037584, ECO:0000269|PubMed:20439989,
CC       ECO:0000269|PubMed:21454698, ECO:0000269|PubMed:23503467,
CC       ECO:0000269|PubMed:23509069, ECO:0000269|PubMed:9422762,
CC       ECO:0000269|PubMed:9756887}.
CC   -!- INTERACTION:
CC       P56945:BCAR1; NbExp=2; IntAct=EBI-702142, EBI-702093;
CC       P46108:CRK; NbExp=3; IntAct=EBI-702142, EBI-886;
CC       P46109:CRKL; NbExp=2; IntAct=EBI-702142, EBI-910;
CC       P00533:EGFR; NbExp=3; IntAct=EBI-702142, EBI-297353;
CC       P29317:EPHA2; NbExp=3; IntAct=EBI-702142, EBI-702104;
CC       P04626:ERBB2; NbExp=2; IntAct=EBI-702142, EBI-641062;
CC       P17948:FLT1; NbExp=2; IntAct=EBI-702142, EBI-1026718;
CC       Q14451:GRB7; NbExp=3; IntAct=EBI-702142, EBI-970191;
CC       P08631-2:HCK; NbExp=2; IntAct=EBI-702142, EBI-9834454;
CC       P16144:ITGB4; NbExp=7; IntAct=EBI-702142, EBI-948678;
CC       Q92569:PIK3R3; NbExp=3; IntAct=EBI-702142, EBI-79893;
CC       Q9H3S7:PTPN23; NbExp=4; IntAct=EBI-702142, EBI-724478;
CC       P29350-3:PTPN6; NbExp=3; IntAct=EBI-702142, EBI-7399369;
CC       Q9Y3E5:PTRH2; NbExp=2; IntAct=EBI-702142, EBI-1056751;
CC       P49023:PXN; NbExp=15; IntAct=EBI-702142, EBI-702209;
CC       Q9NP31:SH2D2A; NbExp=3; IntAct=EBI-702142, EBI-490630;
CC       P12931:SRC; NbExp=8; IntAct=EBI-702142, EBI-621482;
CC       P05480:Src (xeno); NbExp=5; IntAct=EBI-702142, EBI-298680;
CC       O43294:TGFB1I1; NbExp=2; IntAct=EBI-702142, EBI-1051449;
CC       Q62219:Tgfb1i1 (xeno); NbExp=3; IntAct=EBI-702142, EBI-642844;
CC       Q68CZ2:TNS3; NbExp=3; IntAct=EBI-702142, EBI-1220488;
CC       P04637:TP53; NbExp=13; IntAct=EBI-702142, EBI-366083;
CC   -!- SUBCELLULAR LOCATION: Cell junction, focal adhesion. Cell
CC       membrane; Peripheral membrane protein; Cytoplasmic side.
CC       Cytoplasm, cell cortex. Cytoplasm, cytoskeleton. Cytoplasm,
CC       cytoskeleton, microtubule organizing center, centrosome
CC       {ECO:0000250}. Nucleus. Note=Constituent of focal adhesions.
CC       Detected at microtubules.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative promoter usage, Alternative splicing; Named isoforms=7;
CC       Name=1;
CC         IsoId=Q05397-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q05397-2; Sequence=VSP_004967, VSP_004968, VSP_004969,
CC                                  VSP_004970;
CC       Name=3;
CC         IsoId=Q05397-3; Sequence=VSP_004967, VSP_004968, VSP_004969,
CC                                  VSP_004973, VSP_004974;
CC       Name=4;
CC         IsoId=Q05397-4; Sequence=VSP_004967, VSP_004968, VSP_004969,
CC                                  VSP_004971, VSP_004972;
CC       Name=5;
CC         IsoId=Q05397-5; Sequence=VSP_042169, VSP_042170;
CC       Name=6; Synonyms=FRNK;
CC         IsoId=Q05397-6; Sequence=VSP_042168;
CC         Note=Produced by alternative promoter usage.;
CC       Name=7;
CC         IsoId=Q05397-7; Sequence=VSP_057268;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Detected in B and T-lymphocytes. Isoform 1 and
CC       isoform 6 are detected in lung fibroblasts (at protein level).
CC       Ubiquitous. {ECO:0000269|PubMed:20109444,
CC       ECO:0000269|PubMed:7692878, ECO:0000269|PubMed:8247543,
CC       ECO:0000269|PubMed:8422239}.
CC   -!- DEVELOPMENTAL STAGE: Isoform 6 is detected in cultured cells,
CC       immediately after seeding and before formation of focal adhesions
CC       (at protein level).
CC   -!- DOMAIN: The Pro-rich regions interact with the SH3 domain of CAS
CC       family members, such as BCAR1 and NEDD9, and with the GTPase
CC       activating protein ARHGAP26.
CC   -!- DOMAIN: The carboxy-terminal region is the site of focal adhesion
CC       targeting (FAT) sequence which mediates the localization of FAK1
CC       to focal adhesions.
CC   -!- PTM: Phosphorylated on tyrosine residues upon activation, e.g.
CC       upon integrin signaling. Tyr-397 is the major autophosphorylation
CC       site, but other kinases can also phosphorylate this residue.
CC       Phosphorylation at Tyr-397 promotes interaction with SRC and SRC
CC       family members, leading to phosphorylation at Tyr-576, Tyr-577 and
CC       at additional tyrosine residues. FGR promotes phosphorylation at
CC       Tyr-397 and Tyr-576. FER promotes phosphorylation at Tyr-577, Tyr-
CC       861 and Tyr-925, even when cells are not adherent. Tyr-397, Tyr-
CC       576 and Ser-722 are phosphorylated only when cells are adherent.
CC       Phosphorylation at Tyr-397 is important for interaction with BMX,
CC       PIK3R1 and SHC1. Phosphorylation at Tyr-925 is important for
CC       interaction with GRB2. Dephosphorylated by PTPN11; PTPN11 is
CC       recruited to PTK2 via EPHA2 (tyrosine phosphorylated).
CC       Microtubule-induced dephosphorylation at Tyr-397 is crucial for
CC       the induction of focal adhesion disassembly; this
CC       dephosphorylation could be catalyzed by PTPN11 and regulated by
CC       ZFYVE21. {ECO:0000269|PubMed:12387730,
CC       ECO:0000269|PubMed:15561106, ECO:0000269|PubMed:17395594,
CC       ECO:0000269|PubMed:17431114, ECO:0000269|PubMed:18006843,
CC       ECO:0000269|PubMed:19339212, ECO:0000269|PubMed:21454698}.
CC   -!- PTM: Sumoylated; this enhances autophosphorylation. {ECO:0000250}.
CC   -!- DISEASE: Note=Aberrant PTK2/FAK1 expression may play a role in
CC       cancer cell proliferation, migration and invasion, in tumor
CC       formation and metastasis. PTK2/FAK1 overexpression is seen in many
CC       types of cancer.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. FAK subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/PTK2ID41898ch8q24.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L13616; AAA58469.1; -; mRNA.
DR   EMBL; L05186; AAA35819.1; -; mRNA.
DR   EMBL; AK304356; BAG65198.1; -; mRNA.
DR   EMBL; AC067931; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC100860; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC105009; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC105235; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; KF458878; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; KF458882; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC035404; AAH35404.1; -; mRNA.
DR   CCDS; CCDS56557.1; -. [Q05397-5]
DR   CCDS; CCDS6381.1; -. [Q05397-1]
DR   PIR; I53012; I53012.
DR   PIR; PC1225; PC1225.
DR   RefSeq; NP_001186578.1; NM_001199649.1. [Q05397-5]
DR   RefSeq; NP_722560.1; NM_153831.3. [Q05397-1]
DR   RefSeq; XP_016869162.1; XM_017013673.1. [Q05397-1]
DR   UniGene; Hs.395482; -.
DR   PDB; 1K04; X-ray; 1.95 A; A=891-1052.
DR   PDB; 1K05; X-ray; 2.90 A; A/B/C=891-1052.
DR   PDB; 1MP8; X-ray; 1.60 A; A=411-686.
DR   PDB; 1OW6; X-ray; 2.35 A; A/B/C=892-1052.
DR   PDB; 1OW7; X-ray; 2.60 A; A/B/C=892-1052.
DR   PDB; 1OW8; X-ray; 2.85 A; A/B/C=892-1052.
DR   PDB; 2ETM; X-ray; 2.30 A; A/B=411-689.
DR   PDB; 2IJM; X-ray; 2.19 A; A/B=411-689.
DR   PDB; 3B71; X-ray; 2.82 A; A/B/C=891-1052.
DR   PDB; 3BZ3; X-ray; 2.20 A; A=414-689.
DR   PDB; 3PXK; X-ray; 1.79 A; A/B=411-689.
DR   PDB; 3S9O; X-ray; 2.60 A; A/B/C=891-1052.
DR   PDB; 4EBV; X-ray; 1.67 A; A=411-686.
DR   PDB; 4EBW; X-ray; 2.65 A; A=411-686.
DR   PDB; 4GU6; X-ray; 1.95 A; A/B=411-689.
DR   PDB; 4GU9; X-ray; 2.40 A; A/B=410-686.
DR   PDB; 4I4E; X-ray; 1.55 A; A=411-686.
DR   PDB; 4I4F; X-ray; 1.75 A; A=411-686.
DR   PDB; 4K8A; X-ray; 2.91 A; A/B=410-686.
DR   PDB; 4K9Y; X-ray; 2.00 A; A=410-686.
DR   PDB; 4KAB; X-ray; 2.71 A; A/B=410-686.
DR   PDB; 4KAO; X-ray; 2.39 A; A/B=410-689.
DR   PDB; 4NY0; X-ray; 2.80 A; A/B/C/D=31-405.
DR   PDB; 4Q9S; X-ray; 2.07 A; A=411-686.
DR   PDBsum; 1K04; -.
DR   PDBsum; 1K05; -.
DR   PDBsum; 1MP8; -.
DR   PDBsum; 1OW6; -.
DR   PDBsum; 1OW7; -.
DR   PDBsum; 1OW8; -.
DR   PDBsum; 2ETM; -.
DR   PDBsum; 2IJM; -.
DR   PDBsum; 3B71; -.
DR   PDBsum; 3BZ3; -.
DR   PDBsum; 3PXK; -.
DR   PDBsum; 3S9O; -.
DR   PDBsum; 4EBV; -.
DR   PDBsum; 4EBW; -.
DR   PDBsum; 4GU6; -.
DR   PDBsum; 4GU9; -.
DR   PDBsum; 4I4E; -.
DR   PDBsum; 4I4F; -.
DR   PDBsum; 4K8A; -.
DR   PDBsum; 4K9Y; -.
DR   PDBsum; 4KAB; -.
DR   PDBsum; 4KAO; -.
DR   PDBsum; 4NY0; -.
DR   PDBsum; 4Q9S; -.
DR   ProteinModelPortal; Q05397; -.
DR   SMR; Q05397; -.
DR   BioGrid; 111719; 120.
DR   IntAct; Q05397; 69.
DR   MINT; MINT-92695; -.
DR   STRING; 9606.ENSP00000341189; -.
DR   BindingDB; Q05397; -.
DR   ChEMBL; CHEMBL2695; -.
DR   DrugBank; DB07460; 2-({5-CHLORO-2-[(2-METHOXY-4-MORPHOLIN-4-YLPHENYL)AMINO]PYRIMIDIN-4-YL}AMINO)-N-METHYLBENZAMIDE.
DR   GuidetoPHARMACOLOGY; 2180; -.
DR   iPTMnet; Q05397; -.
DR   PhosphoSitePlus; Q05397; -.
DR   BioMuta; PTK2; -.
DR   DMDM; 3183518; -.
DR   EPD; Q05397; -.
DR   MaxQB; Q05397; -.
DR   PaxDb; Q05397; -.
DR   PeptideAtlas; Q05397; -.
DR   PRIDE; Q05397; -.
DR   DNASU; 5747; -.
DR   Ensembl; ENST00000340930; ENSP00000341189; ENSG00000169398. [Q05397-5]
DR   Ensembl; ENST00000395218; ENSP00000378644; ENSG00000169398. [Q05397-7]
DR   Ensembl; ENST00000521059; ENSP00000429474; ENSG00000169398. [Q05397-1]
DR   Ensembl; ENST00000522684; ENSP00000429911; ENSG00000169398. [Q05397-1]
DR   GeneID; 5747; -.
DR   KEGG; hsa:5747; -.
DR   UCSC; uc003yvu.4; human. [Q05397-1]
DR   CTD; 5747; -.
DR   DisGeNET; 5747; -.
DR   GeneCards; PTK2; -.
DR   HGNC; HGNC:9611; PTK2.
DR   HPA; CAB004036; -.
DR   HPA; HPA001842; -.
DR   HPA; HPA029671; -.
DR   MIM; 600758; gene.
DR   neXtProt; NX_Q05397; -.
DR   OpenTargets; ENSG00000169398; -.
DR   PharmGKB; PA33955; -.
DR   eggNOG; KOG4257; Eukaryota.
DR   eggNOG; ENOG410ZH9Y; LUCA.
DR   GeneTree; ENSGT00760000118799; -.
DR   HOGENOM; HOG000069938; -.
DR   HOVERGEN; HBG004018; -.
DR   InParanoid; Q05397; -.
DR   KO; K05725; -.
DR   PhylomeDB; Q05397; -.
DR   TreeFam; TF316643; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   Reactome; R-HSA-111465; Apoptotic cleavage of cellular proteins.
DR   Reactome; R-HSA-2029482; Regulation of actin dynamics for phagocytic cup formation.
DR   Reactome; R-HSA-354192; Integrin alphaIIb beta3 signaling.
DR   Reactome; R-HSA-354194; GRB2:SOS provides linkage to MAPK signaling for Integrins.
DR   Reactome; R-HSA-372708; p130Cas linkage to MAPK signaling for integrins.
DR   Reactome; R-HSA-375165; NCAM signaling for neurite out-growth.
DR   Reactome; R-HSA-391160; Signal regulatory protein (SIRP) family interactions.
DR   Reactome; R-HSA-3928662; EPHB-mediated forward signaling.
DR   Reactome; R-HSA-3928663; EPHA-mediated growth cone collapse.
DR   Reactome; R-HSA-418885; DCC mediated attractive signaling.
DR   Reactome; R-HSA-418886; Netrin mediated repulsion signals.
DR   Reactome; R-HSA-4420097; VEGFA-VEGFR2 Pathway.
DR   Reactome; R-HSA-5663213; RHO GTPases Activate WASPs and WAVEs.
DR   Reactome; R-HSA-5673001; RAF/MAP kinase cascade.
DR   Reactome; R-HSA-8874081; MET activates PTK2 signaling.
DR   SignaLink; Q05397; -.
DR   SIGNOR; Q05397; -.
DR   ChiTaRS; PTK2; human.
DR   EvolutionaryTrace; Q05397; -.
DR   GeneWiki; PTK2; -.
DR   GenomeRNAi; 5747; -.
DR   PMAP-CutDB; Q05397; -.
DR   PRO; PR:Q05397; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   Bgee; ENSG00000169398; -.
DR   CleanEx; HS_PTK2; -.
DR   ExpressionAtlas; Q05397; baseline and differential.
DR   Genevisible; Q05397; HS.
DR   GO; GO:0016324; C:apical plasma membrane; IEA:Ensembl.
DR   GO; GO:0005938; C:cell cortex; IEA:UniProtKB-SubCell.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005856; C:cytoskeleton; TAS:ProtInc.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0031234; C:extrinsic component of cytoplasmic side of plasma membrane; IBA:GO_Central.
DR   GO; GO:0005925; C:focal adhesion; IDA:UniProtKB.
DR   GO; GO:0030027; C:lamellipodium; IEA:Ensembl.
DR   GO; GO:0005815; C:microtubule organizing center; IEA:UniProtKB-SubCell.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0001725; C:stress fiber; IDA:UniProtKB.
DR   GO; GO:0003779; F:actin binding; IDA:BHF-UCL.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0008432; F:JUN kinase binding; IDA:BHF-UCL.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0004672; F:protein kinase activity; TAS:Reactome.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; EXP:Reactome.
DR   GO; GO:0005088; F:Ras guanyl-nucleotide exchange factor activity; TAS:Reactome.
DR   GO; GO:0005102; F:receptor binding; IBA:GO_Central.
DR   GO; GO:0042169; F:SH2 domain binding; IPI:UniProtKB.
DR   GO; GO:0004871; F:signal transducer activity; IEA:InterPro.
DR   GO; GO:0001525; P:angiogenesis; TAS:UniProtKB.
DR   GO; GO:0007411; P:axon guidance; TAS:UniProtKB.
DR   GO; GO:0048870; P:cell motility; TAS:UniProtKB.
DR   GO; GO:0021955; P:central nervous system neuron axonogenesis; IEA:Ensembl.
DR   GO; GO:0009790; P:embryo development; TAS:UniProtKB.
DR   GO; GO:0043542; P:endothelial cell migration; IEA:Ensembl.
DR   GO; GO:0048013; P:ephrin receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0030010; P:establishment of cell polarity; TAS:UniProtKB.
DR   GO; GO:0040023; P:establishment of nucleus localization; IEA:Ensembl.
DR   GO; GO:0097194; P:execution phase of apoptosis; TAS:Reactome.
DR   GO; GO:0030198; P:extracellular matrix organization; IEA:Ensembl.
DR   GO; GO:0038096; P:Fc-gamma receptor signaling pathway involved in phagocytosis; TAS:Reactome.
DR   GO; GO:0060396; P:growth hormone receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0003007; P:heart morphogenesis; TAS:UniProtKB.
DR   GO; GO:0045087; P:innate immune response; IBA:GO_Central.
DR   GO; GO:0007229; P:integrin-mediated signaling pathway; IDA:UniProtKB.
DR   GO; GO:0000165; P:MAPK cascade; TAS:Reactome.
DR   GO; GO:0000226; P:microtubule cytoskeleton organization; IEA:Ensembl.
DR   GO; GO:2000811; P:negative regulation of anoikis; IMP:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0050771; P:negative regulation of axonogenesis; IEA:Ensembl.
DR   GO; GO:0022408; P:negative regulation of cell-cell adhesion; IDA:BHF-UCL.
DR   GO; GO:0046621; P:negative regulation of organ growth; IEA:Ensembl.
DR   GO; GO:0051964; P:negative regulation of synapse assembly; IEA:Ensembl.
DR   GO; GO:0038007; P:netrin-activated signaling pathway; TAS:UniProtKB.
DR   GO; GO:0001764; P:neuron migration; IEA:Ensembl.
DR   GO; GO:0038083; P:peptidyl-tyrosine autophosphorylation; IBA:GO_Central.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0001890; P:placenta development; TAS:UniProtKB.
DR   GO; GO:0030335; P:positive regulation of cell migration; IDA:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; ISS:UniProtKB.
DR   GO; GO:0043552; P:positive regulation of phosphatidylinositol 3-kinase activity; TAS:UniProtKB.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; IMP:UniProtKB.
DR   GO; GO:0045860; P:positive regulation of protein kinase activity; IMP:UniProtKB.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; IMP:UniProtKB.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IMP:UniProtKB.
DR   GO; GO:2000060; P:positive regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process; ISS:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0033628; P:regulation of cell adhesion mediated by integrin; IDA:UniProtKB.
DR   GO; GO:0042127; P:regulation of cell proliferation; IMP:UniProtKB.
DR   GO; GO:0008360; P:regulation of cell shape; IMP:UniProtKB.
DR   GO; GO:0051493; P:regulation of cytoskeleton organization; TAS:UniProtKB.
DR   GO; GO:0010594; P:regulation of endothelial cell migration; TAS:UniProtKB.
DR   GO; GO:0010632; P:regulation of epithelial cell migration; IGI:UniProtKB.
DR   GO; GO:0051893; P:regulation of focal adhesion assembly; IGI:UniProtKB.
DR   GO; GO:0043087; P:regulation of GTPase activity; TAS:UniProtKB.
DR   GO; GO:0045667; P:regulation of osteoblast differentiation; IMP:UniProtKB.
DR   GO; GO:0001932; P:regulation of protein phosphorylation; IGI:UniProtKB.
DR   GO; GO:1900024; P:regulation of substrate adhesion-dependent cell spreading; IGI:UniProtKB.
DR   GO; GO:0007172; P:signal complex assembly; IEA:InterPro.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0001570; P:vasculogenesis; IEA:Ensembl.
DR   Gene3D; 1.20.80.10; -; 1.
DR   InterPro; IPR019749; Band_41_domain.
DR   InterPro; IPR014352; FERM/acyl-CoA-bd_prot_3-hlx.
DR   InterPro; IPR019748; FERM_central.
DR   InterPro; IPR000299; FERM_domain.
DR   InterPro; IPR005189; Focal_adhesion_kin_target_dom.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR011993; PH_dom-like.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR029071; Ubiquitin-rel_dom.
DR   Pfam; PF00373; FERM_M; 1.
DR   Pfam; PF03623; Focal_AT; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   ProDom; PD006413; Focal_adhesion_target_reg; 1.
DR   SMART; SM00295; B41; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF47031; SSF47031; 1.
DR   SUPFAM; SSF50729; SSF50729; 1.
DR   SUPFAM; SSF54236; SSF54236; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF68993; SSF68993; 1.
DR   PROSITE; PS00661; FERM_2; 1.
DR   PROSITE; PS50057; FERM_3; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative promoter usage;
KW   Alternative splicing; Angiogenesis; ATP-binding; Cell junction;
KW   Cell membrane; Complete proteome; Cytoplasm; Cytoskeleton;
KW   Developmental protein; Direct protein sequencing; Isopeptide bond;
KW   Kinase; Membrane; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Polymorphism; Reference proteome; Transferase;
KW   Tyrosine-protein kinase; Ubl conjugation.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:19413330,
FT                                ECO:0000269|Ref.6}.
FT   CHAIN         2   1052       Focal adhesion kinase 1.
FT                                /FTId=PRO_0000088077.
FT   DOMAIN       35    355       FERM. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00084}.
FT   DOMAIN      422    680       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     428    434       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159,
FT                                ECO:0000269|PubMed:12467573}.
FT   NP_BIND     500    502       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159,
FT                                ECO:0000269|PubMed:12467573}.
FT   REGION      707   1052       Interaction with TGFB1I1.
FT   REGION      912   1052       Interaction with ARHGEF28. {ECO:0000250}.
FT   COMPBIAS    712    733       Pro-rich.
FT   COMPBIAS    863    913       Pro-rich.
FT   ACT_SITE    546    546       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     454    454       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159,
FT                                ECO:0000269|PubMed:12467573}.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:19413330,
FT                                ECO:0000269|Ref.6}.
FT   MOD_RES       5      5       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES      13     13       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES      29     29       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES      54     54       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P34152}.
FT   MOD_RES     397    397       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000244|PubMed:19369195,
FT                                ECO:0000269|PubMed:12387730,
FT                                ECO:0000269|PubMed:15561106,
FT                                ECO:0000269|PubMed:17395594,
FT                                ECO:0000269|PubMed:17431114,
FT                                ECO:0000269|PubMed:18006843,
FT                                ECO:0000269|PubMed:19339212}.
FT   MOD_RES     407    407       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:12387730,
FT                                ECO:0000269|PubMed:15561106}.
FT   MOD_RES     570    570       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     576    576       Phosphotyrosine; by RET and SRC.
FT                                {ECO:0000269|PubMed:15561106,
FT                                ECO:0000269|PubMed:19339212,
FT                                ECO:0000269|PubMed:21454698}.
FT   MOD_RES     577    577       Phosphotyrosine; by RET and SRC.
FT                                {ECO:0000269|PubMed:12387730,
FT                                ECO:0000269|PubMed:19339212,
FT                                ECO:0000269|PubMed:21454698}.
FT   MOD_RES     580    580       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     722    722       Phosphoserine.
FT                                {ECO:0000269|PubMed:19339212}.
FT   MOD_RES     732    732       Phosphoserine; by CDK5. {ECO:0000250}.
FT   MOD_RES     843    843       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     861    861       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:12387730,
FT                                ECO:0000269|PubMed:18006843,
FT                                ECO:0000269|PubMed:19339212}.
FT   MOD_RES     887    887       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976}.
FT   MOD_RES     910    910       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     914    914       Phosphothreonine.
FT                                {ECO:0000244|PubMed:20068231}.
FT   MOD_RES     925    925       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:12387730,
FT                                ECO:0000269|PubMed:19339212}.
FT   CROSSLNK    152    152       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO).
FT                                {ECO:0000250}.
FT   VAR_SEQ       1    692       Missing (in isoform 6). {ECO:0000305}.
FT                                /FTId=VSP_042168.
FT   VAR_SEQ       1    181       Missing (in isoform 2, isoform 3 and
FT                                isoform 4). {ECO:0000303|PubMed:8422239}.
FT                                /FTId=VSP_004967.
FT   VAR_SEQ     182    189       EMRGNALE -> MSDYWVVG (in isoform 2,
FT                                isoform 3 and isoform 4).
FT                                {ECO:0000303|PubMed:8422239}.
FT                                /FTId=VSP_004968.
FT   VAR_SEQ     472    472       A -> ACHYTSLHWNWCRYISDPNVDACPDPRNAE (in
FT                                isoform 2, isoform 3 and isoform 4).
FT                                {ECO:0000303|PubMed:8422239}.
FT                                /FTId=VSP_004969.
FT   VAR_SEQ     579    583       ASKGK -> GKKSG (in isoform 4).
FT                                {ECO:0000303|PubMed:8422239}.
FT                                /FTId=VSP_004971.
FT   VAR_SEQ     584   1052       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:8422239}.
FT                                /FTId=VSP_004972.
FT   VAR_SEQ     677    706       STILEEEKAQQEERMRMESRRQATVSWDSG -> FQNPAQM
FT                                LPASGRLPNQPCPERENYSFATF (in isoform 3).
FT                                {ECO:0000303|PubMed:8422239}.
FT                                /FTId=VSP_004973.
FT   VAR_SEQ     707   1052       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:8422239}.
FT                                /FTId=VSP_004974.
FT   VAR_SEQ     744    789       Missing (in isoform 7).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_057268.
FT   VAR_SEQ     834    854       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:8422239}.
FT                                /FTId=VSP_004970.
FT   VAR_SEQ     868    868       D -> GKEEKNWAERN (in isoform 5).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_042169.
FT   VAR_SEQ     903    903       K -> KPWR (in isoform 5).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_042170.
FT   VARIANT     292    292       H -> P. {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041682.
FT   VARIANT     292    292       H -> Q. {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041683.
FT   VARIANT     793    793       V -> A (in a glioblastoma multiforme
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041684.
FT   VARIANT    1030   1030       D -> E. {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041685.
FT   VARIANT    1044   1044       K -> E (in a metastatic melanoma sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041686.
FT   MUTAGEN     397    397       Y->F: Abolishes autophosphorylation.
FT                                Abolishes interaction with SRC and
FT                                activation of BMX.
FT                                {ECO:0000269|PubMed:11331870}.
FT   MUTAGEN     928    928       V->G: Loss of interaction with TGFB1I1.
FT                                {ECO:0000269|PubMed:9756887}.
FT   MUTAGEN    1034   1034       L->S: Loss of interaction with TGFB1I1.
FT                                {ECO:0000269|PubMed:9756887}.
FT   CONFLICT    184    184       R -> L (in Ref. 3; BAG65198).
FT                                {ECO:0000305}.
FT   CONFLICT    211    211       L -> I (in Ref. 3; BAG65198).
FT                                {ECO:0000305}.
FT   CONFLICT    778    778       P -> S (in Ref. 2; AAA35819).
FT                                {ECO:0000305}.
FT   STRAND       35     40       {ECO:0000244|PDB:4NY0}.
FT   HELIX        49     51       {ECO:0000244|PDB:4NY0}.
FT   STRAND       53     58       {ECO:0000244|PDB:4NY0}.
FT   HELIX        64     73       {ECO:0000244|PDB:4NY0}.
FT   TURN         74     76       {ECO:0000244|PDB:4NY0}.
FT   HELIX        80     82       {ECO:0000244|PDB:4NY0}.
FT   STRAND       83     89       {ECO:0000244|PDB:4NY0}.
FT   STRAND       95     98       {ECO:0000244|PDB:4NY0}.
FT   HELIX       104    114       {ECO:0000244|PDB:4NY0}.
FT   HELIX       117    119       {ECO:0000244|PDB:4NY0}.
FT   STRAND      120    126       {ECO:0000244|PDB:4NY0}.
FT   HELIX       133    137       {ECO:0000244|PDB:4NY0}.
FT   HELIX       141    158       {ECO:0000244|PDB:4NY0}.
FT   HELIX       165    179       {ECO:0000244|PDB:4NY0}.
FT   HELIX       185    187       {ECO:0000244|PDB:4NY0}.
FT   STRAND      188    190       {ECO:0000244|PDB:4NY0}.
FT   HELIX       191    194       {ECO:0000244|PDB:4NY0}.
FT   HELIX       197    201       {ECO:0000244|PDB:4NY0}.
FT   TURN        204    206       {ECO:0000244|PDB:4NY0}.
FT   HELIX       209    214       {ECO:0000244|PDB:4NY0}.
FT   TURN        217    219       {ECO:0000244|PDB:4NY0}.
FT   HELIX       220    228       {ECO:0000244|PDB:4NY0}.
FT   HELIX       229    231       {ECO:0000244|PDB:4NY0}.
FT   HELIX       236    247       {ECO:0000244|PDB:4NY0}.
FT   HELIX       248    250       {ECO:0000244|PDB:4NY0}.
FT   STRAND      256    262       {ECO:0000244|PDB:4NY0}.
FT   STRAND      264    266       {ECO:0000244|PDB:4NY0}.
FT   STRAND      268    275       {ECO:0000244|PDB:4NY0}.
FT   TURN        276    278       {ECO:0000244|PDB:4NY0}.
FT   STRAND      279    283       {ECO:0000244|PDB:4NY0}.
FT   STRAND      290    294       {ECO:0000244|PDB:4NY0}.
FT   HELIX       296    298       {ECO:0000244|PDB:4NY0}.
FT   STRAND      299    306       {ECO:0000244|PDB:4NY0}.
FT   STRAND      308    311       {ECO:0000244|PDB:4NY0}.
FT   STRAND      314    320       {ECO:0000244|PDB:4NY0}.
FT   STRAND      327    333       {ECO:0000244|PDB:4NY0}.
FT   HELIX       334    351       {ECO:0000244|PDB:4NY0}.
FT   HELIX       413    415       {ECO:0000244|PDB:4EBV}.
FT   HELIX       419    421       {ECO:0000244|PDB:4I4E}.
FT   STRAND      422    430       {ECO:0000244|PDB:4I4E}.
FT   STRAND      432    441       {ECO:0000244|PDB:4I4E}.
FT   STRAND      444    446       {ECO:0000244|PDB:4K9Y}.
FT   STRAND      448    455       {ECO:0000244|PDB:4I4E}.
FT   TURN        457    460       {ECO:0000244|PDB:4I4E}.
FT   HELIX       462    468       {ECO:0000244|PDB:4I4E}.
FT   HELIX       470    476       {ECO:0000244|PDB:4I4E}.
FT   STRAND      486    490       {ECO:0000244|PDB:4I4E}.
FT   STRAND      492    494       {ECO:0000244|PDB:4I4E}.
FT   STRAND      496    500       {ECO:0000244|PDB:4I4E}.
FT   HELIX       507    513       {ECO:0000244|PDB:4I4E}.
FT   TURN        514    517       {ECO:0000244|PDB:4I4E}.
FT   HELIX       520    539       {ECO:0000244|PDB:4I4E}.
FT   HELIX       549    551       {ECO:0000244|PDB:4I4E}.
FT   STRAND      552    556       {ECO:0000244|PDB:4I4E}.
FT   STRAND      559    562       {ECO:0000244|PDB:4I4E}.
FT   HELIX       565    568       {ECO:0000244|PDB:4GU6}.
FT   HELIX       570    573       {ECO:0000244|PDB:4GU6}.
FT   HELIX       574    576       {ECO:0000244|PDB:4GU6}.
FT   HELIX       586    588       {ECO:0000244|PDB:4I4E}.
FT   HELIX       591    596       {ECO:0000244|PDB:4I4E}.
FT   HELIX       601    616       {ECO:0000244|PDB:4I4E}.
FT   TURN        617    619       {ECO:0000244|PDB:4EBV}.
FT   TURN        622    625       {ECO:0000244|PDB:4I4E}.
FT   HELIX       628    630       {ECO:0000244|PDB:4I4E}.
FT   HELIX       631    636       {ECO:0000244|PDB:4I4E}.
FT   HELIX       649    658       {ECO:0000244|PDB:4I4E}.
FT   HELIX       663    665       {ECO:0000244|PDB:4I4E}.
FT   HELIX       669    684       {ECO:0000244|PDB:4I4E}.
FT   HELIX       685    687       {ECO:0000244|PDB:2IJM}.
FT   STRAND      915    917       {ECO:0000244|PDB:1K04}.
FT   HELIX       923    942       {ECO:0000244|PDB:1K04}.
FT   HELIX       947    949       {ECO:0000244|PDB:1K04}.
FT   HELIX       950    971       {ECO:0000244|PDB:1K04}.
FT   HELIX       972    974       {ECO:0000244|PDB:1K04}.
FT   HELIX       977    979       {ECO:0000244|PDB:1K04}.
FT   HELIX       980   1006       {ECO:0000244|PDB:1K04}.
FT   TURN       1007   1009       {ECO:0000244|PDB:1K04}.
FT   STRAND     1010   1012       {ECO:0000244|PDB:1K04}.
FT   HELIX      1013   1045       {ECO:0000244|PDB:1K04}.
SQ   SEQUENCE   1052 AA;  119233 MW;  D8A4C15138AB0243 CRC64;
     MAAAYLDPNL NHTPNSSTKT HLGTGMERSP GAMERVLKVF HYFESNSEPT TWASIIRHGD
     ATDVRGIIQK IVDSHKVKHV ACYGFRLSHL RSEEVHWLHV DMGVSSVREK YELAHPPEEW
     KYELRIRYLP KGFLNQFTED KPTLNFFYQQ VKSDYMLEIA DQVDQEIALK LGCLEIRRSY
     WEMRGNALEK KSNYEVLEKD VGLKRFFPKS LLDSVKAKTL RKLIQQTFRQ FANLNREESI
     LKFFEILSPV YRFDKECFKC ALGSSWIISV ELAIGPEEGI SYLTDKGCNP THLADFTQVQ
     TIQYSNSEDK DRKGMLQLKI AGAPEPLTVT APSLTIAENM ADLIDGYCRL VNGTSQSFII
     RPQKEGERAL PSIPKLANSE KQGMRTHAVS VSETDDYAEI IDEEDTYTMP STRDYEIQRE
     RIELGRCIGE GQFGDVHQGI YMSPENPALA VAIKTCKNCT SDSVREKFLQ EALTMRQFDH
     PHIVKLIGVI TENPVWIIME LCTLGELRSF LQVRKYSLDL ASLILYAYQL STALAYLESK
     RFVHRDIAAR NVLVSSNDCV KLGDFGLSRY MEDSTYYKAS KGKLPIKWMA PESINFRRFT
     SASDVWMFGV CMWEILMHGV KPFQGVKNND VIGRIENGER LPMPPNCPPT LYSLMTKCWA
     YDPSRRPRFT ELKAQLSTIL EEEKAQQEER MRMESRRQAT VSWDSGGSDE APPKPSRPGY
     PSPRSSEGFY PSPQHMVQTN HYQVSGYPGS HGITAMAGSI YPGQASLLDQ TDSWNHRPQE
     IAMWQPNVED STVLDLRGIG QVLPTHLMEE RLIRQQQEME EDQRWLEKEE RFLKPDVRLS
     RGSIDREDGS LQGPIGNQHI YQPVGKPDPA APPKKPPRPG APGHLGSLAS LSSPADSYNE
     GVKLQPQEIS PPPTANLDRS NDKVYENVTG LVKAVIEMSS KIQPAPPEEY VPMVKEVGLA
     LRTLLATVDE TIPLLPASTH REIEMAQKLL NSDLGELINK MKLAQQYVMT SLQQEYKKQM
     LTAAHALAVD AKNLLDVIDQ ARLKMLGQTR PH
//
